Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 14/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340855 | 0.86 | CXCR2 (0.45) | CXCR2 | |
| SCHEMBL954898 | 0.85 | CXCR2 (0.49) | CXCR2ALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL30515692 | 0.85 | CXCR2 (0.49) | CXCR2ALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL3337830 | 0.85 | CXCR2 (0.52) | CXCR2KDM4ENPC1RAB9AMAPT | |
| SCHEMBL3338767 | 0.85 | CXCR2 (0.43) | CXCR2ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3343130 | 0.84 | CXCR2 (0.58) | CXCR2RAB9A | |
| SCHEMBL3343981 | 0.84 | CXCR2 (0.47) | CXCR2ALDH1A1KDM4ESMN1; SMN2RAB9A | |
| SCHEMBL3338731 | 0.83 | CXCR2 (0.46) | CXCR2 | |
| SCHEMBL3336538 | 0.83 | CXCR2 (0.49) | CXCR2 | |
| SCHEMBL2638147 | 0.82 | CXCR2 (0.52) | CXCR2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | claimed |
| EP-2094697-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
| US-20100152205-A1 | CXCR2 INHIBITORS | NOVARTIS AG | 2010-06-17 | — | — | US | disclosed |
| EP-2094697-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008062026-A1 | 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152205-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885ALDH1A1 931/4885KDM4E 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.